Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.59−0.07 (-10.00%)
Close on Nov 13, 2026Market cap $1.07MP/E –Yield –
Aptevo Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Aptevo Therapeutics's operating margin for the twelve months ending Dec 31, 2022 was -919.7%. For fiscal 2022 it was -919.7%, against -174.1% the year before. The highest annual figure on record is -126.3% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -919.7% | −745.7 |
| FY2021 | Dec 31, 2021 | -174.1% | +464.0 |
| FY2020 | Dec 31, 2020 | -638.1% | −511.7 |
| FY2019 | Dec 31, 2019 | -126.3% | +97.6 |
| FY2018 | Dec 31, 2018 | -224.0% | +144.1 |
| FY2017 | Dec 31, 2017 | -368.1% | +1021.8 |
| FY2016 | Dec 31, 2016 | -1389.8% | −1208.0 |
| FY2015 | Dec 31, 2015 | -181.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | -180.2% | +104.3 |
| Q4 FY2021 | Dec 31, 2021 | -110.2% | +177.1 |
| Q3 FY2021 | Sep 30, 2021 | -153.4% | +273.5 |
| Q2 FY2021 | Jun 30, 2021 | -184.0% | +1255.1 |
| Q1 FY2021 | Mar 31, 2021 | -284.5% | −196.6 |
| Q4 FY2020 | Dec 31, 2020 | -287.4% | −160.2 |
| Q3 FY2020 | Sep 30, 2020 | -426.9% | −251.7 |
| Q2 FY2020 | Jun 30, 2020 | -1439.1% | −1276.2 |
| Q4 FY2019 | Dec 31, 2019 | -87.9% | +126.3 |
| Q3 FY2019 | Sep 30, 2019 | -127.2% | +81.1 |
| Q2 FY2019 | Jun 30, 2019 | -175.2% | +7.1 |
| Q1 FY2019 | Mar 31, 2019 | -162.9% | +168.7 |
| Q4 FY2018 | Dec 31, 2018 | -214.2% | +382.7 |
| Q3 FY2018 | Sep 30, 2018 | -208.2% | −40.6 |
| Q2 FY2018 | Jun 30, 2018 | -182.3% | +233.2 |
| Q1 FY2018 | Mar 31, 2018 | -331.6% | +234.7 |
| Q4 FY2017 | Dec 31, 2017 | -596.9% | −431.0 |
| Q3 FY2017 | Sep 30, 2017 | -167.7% | +3047.0 |
| Q2 FY2017 | Jun 30, 2017 | -415.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -566.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -166.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -3214.7% | – |
See a number that looks wrong?